While the medication is now reaching patients, its path to availability in Sweden has faced significant hurdles. In April 2026, the New Therapies Council, NT-rådet, issued a negative recommendation regarding the drug's inclusion in the country's publicly funded healthcare system. In response to this decision, Executive Health in Stockholm moved to independently offer the therapy to those diagnosed with early-stage Alzheimer’s disease.

BioArctic CEO Gunilla Osswald noted the significance of the rollout, which stems from research originally conducted by Professor Lars Lannfelt at Uppsala University. Leqembi is specifically indicated for adults with mild cognitive impairment or mild dementia who meet precise clinical and genetic criteria, including confirmed amyloid pathology. The drug represents a long-term collaboration between BioArctic and Eisai, designed to target the underlying causes of the disease rather than merely addressing symptoms.